TRexBio closed a $50 million Series B extension to fund clinical development of Treg‑activating candidates, including TRB‑061 for atopic dermatitis, and to advance two additional programs into early human testing. Investors in the extension included Janus Henderson, Alexandria Venture Investments and Eli Lilly. TRex’s approach targets TNFR2‑expressing regulatory T cells to modulate inflammation, positioning the company amid a crowded next‑generation eczema field with assets from Corvus, Apogee and others.